How to Get Low-Dose Naltrexone in Wyoming

What Low-Dose Naltrexone Is and Why It Is Prescribed Off-Label

Low-dose naltrexone refers to naltrexone taken at 1.5 mg to 4.5 mg nightly, which is roughly one-tenth of the 50 mg dose the FDA approved for opioid and alcohol use disorder. At this sub-pharmacological range, the drug is thought to transiently block opioid receptors for two to four hours, which may trigger a rebound upregulation of endogenous opioids and reduce microglial activation, a key driver of central sensitization and systemic inflammation.

The Evidence Base for LDN

The clinical trial most often cited in LDN literature is Younger et al. (Pain Medicine, 2009), a crossover pilot (N=10) that found LDN reduced fibromyalgia symptom severity by 30% compared with placebo (P<0.05) [1]. A follow-up randomized controlled trial by the same group (N=31, 2013) confirmed a statistically significant pain reduction of approximately 28.8% versus placebo, with a notably clean adverse-effect profile [2].

Autoimmune research adds to this picture. A 2018 review published in Frontiers in Psychiatry examined LDN across multiple inflammatory conditions, including Crohn's disease, multiple sclerosis, and complex regional pain syndrome, and concluded that the drug's tolerability and low cost make it a candidate for larger controlled trials [3]. The authors noted that LDN "appears to be the most promising, low-cost intervention available" for neuroinflammatory conditions, though they acknowledged that most data come from small trials.

What LDN Is Not Approved For

The FDA has not approved any formulation of naltrexone below 50 mg for any indication [4]. Prescribers who write LDN orders are doing so under established off-label prescribing authority, which is legal in all U.S. States including Wyoming. The compounded capsules dispensed by 503A pharmacies are not the same product as Vivitrol (injectable naltrexone) or Revia (oral 50 mg naltrexone), both of which are FDA-approved products [4].

Who Can Prescribe LDN in Wyoming

Any clinician holding an active Wyoming DEA registration and a Wyoming prescribing license may write a compounding script for LDN. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) operating within their scope.

Scope of Practice for NPs and PAs

Wyoming is a full practice authority state for nurse practitioners as of 2022, meaning NPs can evaluate, diagnose, and prescribe independently without a required physician collaboration agreement [5]. PAs in Wyoming operate under a job description model, they may prescribe Schedule III and non-scheduled medications, including compounded naltrexone, when their practice agreement permits [6].

This matters for telehealth patients: an NP-led telehealth platform with Wyoming licensure can legally initiate an LDN prescription after a single synchronous video visit, or in some cases after an asynchronous intake if state telehealth regulations allow it.

Does the Prescriber Need Wyoming Licensure?

Yes. A clinician physically located in another state must hold an active Wyoming medical or advanced-practice license to prescribe to a Wyoming-based patient. Multi-state compact membership (through the Interstate Medical Licensure Compact or the APRN Compact) simplifies this process for many telehealth providers, but Wyoming patients should confirm licensure before their consultation [7].

Telehealth Options for LDN in Wyoming

Wyoming's low population density, roughly 580,000 residents spread across 97,000 square miles, makes telehealth a practical first choice for most LDN seekers. The state has had a formal telehealth statute since 2018 (Wyoming Statute §33-26-102) and explicitly allows clinicians to prescribe non-controlled substances after a real-time audio-visual encounter.

How a Typical Telehealth LDN Consult Works

1. Intake form. Most platforms collect your symptom history, prior medications, and any current opioid use (LDN is contraindicated if you are on full-agonist opioids) before scheduling.
2. Synchronous visit. A 20- to 40-minute video call with a licensed clinician. Expect questions about your diagnosis, prior treatments, and liver history.
3. Lab order. The clinician may send a lab requisition to a draw site near you, or accept recent results (within 90 days) you upload through the portal.
4. Prescription transmission. The script is sent electronically to your chosen 503A compounding pharmacy.
5. Dispensing and shipping. Most 503A pharmacies ship directly to Wyoming addresses; delivery typically takes three to seven business days after the pharmacy receives the prescription.

What Telehealth Platforms Cannot Do

Telehealth prescribers in Wyoming cannot prescribe LDN to a patient currently receiving opioid agonist therapy (buprenorphine, methadone) for opioid use disorder without direct coordination with the OUD treatment team, because LDN at any dose could precipitate withdrawal [8]. Patients with acute hepatitis or severe hepatic impairment (ALT or AST greater than three to five times the upper limit of normal) should not start naltrexone at any dose per the FDA prescribing label [4].

Labs Required Before Starting LDN in Wyoming

Most prescribers require at least a liver function panel before initiating LDN. The FDA's full-dose naltrexone labeling warns of hepatotoxicity at doses above 50 mg, but standard practice for off-label low-dose use still includes baseline LFTs [4].

Standard Lab Panel

• Liver function tests (LFTs): ALT, AST, total bilirubin, alkaline phosphatase. Naltrexone is hepatically metabolized, so elevated baseline values may prompt dose adjustment or a different approach.
• Comprehensive metabolic panel (CMP): Provides creatinine, glucose, electrolytes, and additional liver markers in one draw.
• TSH (optional but common for autoimmune indications): Many clinicians prescribing LDN for Hashimoto's thyroiditis or other autoimmune conditions add a thyroid panel.
• CBC (optional): Ordered at clinician discretion, particularly in patients with inflammatory bowel disease where anemia is common.

Results can usually be obtained at a Quest Diagnostics, LabCorp, or hospital outpatient lab in Cheyenne, Casper, Laramie, Gillette, or Jackson. Rural Wyoming patients near Wyoming's frontier counties may need to drive 60 to 90 minutes to a draw site; some telehealth platforms partner with mobile phlebotomy services that cover Wyoming zip codes.

How Recent Do Labs Need to Be?

Most telehealth clinicians accept LFT results drawn within 90 days. If you had a CMP during a recent annual physical, upload it at intake, it may satisfy the requirement and save you a separate lab visit.

503A Compounding Pharmacies and Wyoming Law

Low-dose naltrexone is not manufactured by any FDA-approved drug sponsor at doses below 50 mg, so every LDN prescription must be filled by a 503A compounding pharmacy [4]. A 503A pharmacy compounds for individual patient prescriptions (as opposed to 503B outsourcing facilities, which produce bulk stock).

Wyoming's Compounding Pharmacy Regulations

Wyoming follows USP <795> and USP <800> standards for non-sterile compounding, administered by the Wyoming State Board of Pharmacy [9]. A compounding pharmacy does not need to be physically located in Wyoming to dispense to Wyoming patients, it must hold a Wyoming non-resident pharmacy permit. Most large LDN-focused compounding pharmacies (such as those in Texas, Florida, or California) already hold multi-state permits covering Wyoming.

Choosing a 503A Pharmacy

When evaluating a compounding pharmacy for your LDN script, confirm:

• Active Wyoming non-resident pharmacy permit (searchable on the Wyoming Board of Pharmacy license lookup)
• PCAB accreditation or state board inspection history
• Independent potency testing for each LDN batch (ask for a certificate of analysis)
• Capsule excipient list, some patients with mast cell activation syndrome or multiple chemical sensitivities react to fillers like lactose or magnesium stearate; calcium carbonate or microcrystalline cellulose are common alternatives

Standard LDN formulations are oral capsules dosed at 1.5 mg, 3.0 mg, or 4.5 mg. Some pharmacies also offer a liquid formulation (naltrexone 1 mg/mL) for titrating patients who need finer dose adjustments. Liquid formulations require careful storage and a short shelf life, typically 30 days refrigerated.

Dosing Protocol and How to Titrate

Most clinicians follow a titration schedule developed from Younger's fibromyalgia protocols and adapted by the LDN Research Trust clinical guidance document [10].

Common Starting Protocol

• Weeks 1 to 2: 1.5 mg nightly at bedtime
• Weeks 3 to 4: 3.0 mg nightly if tolerating well
• Week 5 onward: 4.5 mg nightly as target maintenance dose

The drug is taken at bedtime because its receptor-blocking window (two to four hours) overlaps with overnight endorphin release patterns, and most patients find that any vivid dreaming or mild sleep disruption, the most common early side effects, is easier to tolerate than daytime dosing [1].

When to Adjust Dose

Some patients stabilize at 3.0 mg rather than 4.5 mg, particularly those with thyroid autoimmunity. A small subset reports better results at doses as low as 0.5 mg to 1.5 mg; this ultra-low-dose range requires a different compounding specification and is less commonly prescribed. If a patient has not noticed any symptomatic change after eight weeks at 4.5 mg, the prescriber should reassess the diagnosis rather than automatically increasing the dose, there is no established evidence for doses above 4.5 mg in the inflammatory indications [1, 2].

Cost, Insurance, and Prior Authorization in Wyoming

Wyoming Medicaid does not cover LDN for off-label indications including fibromyalgia, autoimmune disease, or general inflammation. Private insurers in Wyoming occasionally cover compounded medications, but prior authorization for an off-label compounded drug is rarely approved without extensive documentation.

Prior Authorization Documentation Requirements

If you choose to attempt prior authorization through a private Wyoming insurer, your prescriber will typically need to submit:

• A written letter of medical necessity citing the specific diagnosis (ICD-10 code), failed prior treatments, and supporting clinical literature
• A copy of at least one peer-reviewed trial (Younger et al. 2009 [1] and 2013 [2] are the most commonly submitted)
• Documentation that standard-of-care treatments were tried and were insufficient or not tolerated
• The prescriber's clinical notes from the evaluating visit

Approval rates remain low. Most Wyoming LDN patients pay cash. Monthly costs through a 503A pharmacy typically run $30 to $80 depending on dose and the pharmacy's pricing structure, making LDN one of the more affordable compounded medications available.

FSA and HSA Eligibility

Compounded prescription medications dispensed by a licensed pharmacy are generally FSA/HSA-eligible when prescribed by a licensed clinician for a specific medical condition. Keep your pharmacy receipt and the prescription label as documentation. The IRS guidance in Publication 502 governs medical expense deductibility, and compounded prescription drugs meet the "prescribed drug" definition when dispensed pursuant to a valid prescription [11].

Transfer of Existing LDN Prescriptions to Wyoming

Patients relocating to Wyoming who already have an LDN prescription from another state cannot simply transfer the script to a new pharmacy without clinician involvement. Compounded medications are not transferable under federal law the way commercially manufactured prescriptions are, each fill must originate from a valid prescription issued to the specific patient by a licensed prescriber [9].

Steps for Prescription Continuity

1. Contact your existing prescribing clinician and ask them to reissue the prescription to a Wyoming-licensed compounding pharmacy, if they hold Wyoming prescribing authority.
2. If your prior clinician is not Wyoming-licensed, schedule a new consultation with a Wyoming-registered telehealth provider. Many platforms will accept your prior records and treatment history to simplify the visit.
3. Ask your current 503A pharmacy whether they hold a Wyoming non-resident permit. If they do, the prescriber can send a new script directly to them, avoiding any gap in therapy.

Contraindications and Safety Monitoring

Naltrexone at any dose is contraindicated in patients currently using opioid agonists, because even sub-pharmacological doses may precipitate acute withdrawal [4, 8]. Patients must be opioid-free for a minimum of seven to ten days (14 days for long-acting opioids) before starting LDN.

Ongoing Monitoring Schedule

After the initial LFT baseline, most clinicians repeat liver enzymes at three months and then annually if results remain stable. The 2009 Younger pilot reported no significant liver enzyme elevations at doses of 4.5 mg [1], which aligns with the expectation that hepatotoxicity risk at sub-5 mg doses is far lower than at the 50 mg therapeutic range. Still, any patient who develops jaundice, right upper quadrant pain, or unexplained fatigue after starting LDN should have LFTs checked promptly.

Drug Interactions to Discuss at Your Consult

• Opioid analgesics: Absolute contraindication, LDN blocks opioid receptors and will precipitate withdrawal or render opioid medications ineffective [4, 8].
• Thioridazine: Case reports suggest potential interaction; avoid concurrent use.
• Immunosuppressants: Patients on cyclosporine, tacrolimus, or mycophenolate for autoimmune conditions may see unpredictable immune modulation; the interaction is not well characterized in controlled trials [3].
• Thyroid hormone replacement: No pharmacokinetic interaction is documented, but some Hashimoto's patients find they need thyroid dose recalibration after LDN stabilizes their inflammatory state, a clinically relevant consideration, not a contraindication [2].

Realistic Timelines: From Decision to First Dose

Wyoming patients asking "how long until I receive LDN" should plan for this approximate sequence:

• Day 1 to 2: Schedule and complete telehealth consult. Many platforms offer next-day appointments.
• Day 2 to 5: Complete lab draw at a local facility (if labs not already available). Results typically return within 24 to 72 hours.
• Day 5 to 7: Prescriber reviews labs and transmits prescription electronically to your chosen 503A pharmacy.
• Day 7 to 14: Pharmacy compounds and ships your order. Ground shipping from most domestic compounding pharmacies reaches Wyoming in three to five business days.

Patients who already have recent labs and can provide them at intake can compress this timeline to seven days or fewer. Rural patients in frontier Wyoming counties, Niobrara, Hot Springs, Crook, should plan for the longer end of the range due to shipping logistics.